You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Iadonato S, Ovechkina Y, Lustig K, et al
1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1357